NOVANTA INC

• 10-QQ2 FY2026MixedRestructuring

  Filed Aug 5

  Riverpoint Medical acquisition expands minimally invasive surgical consumables exposure but sharply raises debt and integration risk.

  • Revenue$265.8MYoY +10.3%
  • Net income$12.5MYoY +178.9%

• 8-KPositiveEarningsNew guidance

  Filed Aug 5

  Riverpoint Medical acquisition roughly doubles recurring medical consumables to ≈25% of annualized sales; immediate margin and EPS gains expected.

• 8-KPositiveDeal completedDebt financing

  Filed Jul 27

  Riverpoint Medical acquisition closes for ≈$1.2B cash plus a $250M milestone payment, expected to double recurring medical consumables revenue.

Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.

Request longer coverage